{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Number of participants with relapse at 1 year.\n\nPatients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.","groups":[{"description":"Subjects with hematological malignancies with prior autologous transplant, \\>2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months, OR subjects with refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy.\n\n* Cyclophosphamide 50 mg/Kg Day -6\n* Fludarabine 40mg/m2 Days -6 to -2\n* TBI 200 cGy Day -1\n\nImmune suppression: begin Day -3 cyclosporine and mycophenolate mofetil","id":"OG000","title":"Cyclophosphamide/Fludarabine/TBI"},{"description":"Subjects with hematological malignancies with prior autologous transplant \\>12 mos or \\<1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months.\n\n* Cyclophosphamide 50 mg/Kg Day -6\n* Fludarabine 40mg/m2 Days -6 to -2\n* TBI 200 cGy Day -1\n* Equine ATG 30mg/Kg Days -6 to -4\n\nImmune suppression: begin Day -3 cyclosporine and mycophenolate mofetil","id":"OG001","title":"Cyclophosphamide/Fludarabine/TBI/ATG"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year post transplant","title":"Incidence of Relapse at 1 Year","type":"SECONDARY","unitOfMeasure":"Participants"}